|
1.
|
Boku N, Yamamoto S, Fukuda H, et al
Gastrointestinal Oncology Study Group of the Japan Clinical
Oncology Group: Fluorouracil versus combination of irinotecan plus
cisplatin versus S-1 in metastatic gastric cancer: a randomised
phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Shitara K, Oze I, Mizota A, et al:
Randomized phase II study comparing dose escalated weekly
paclitaxel vs. standard dose weekly paclitaxel for patients with
previously treated advanced gastric cancer. Jpn J Clin Oncol.
41:287–290. 2011. View Article : Google Scholar
|
|
4.
|
Shimoyama R, Yasui H, Boku N, et al:
Weekly paclitaxel for heavily treated advanced or recurrent gastric
cancer refractory to fluorouracil, irinotecan, and cisplatin.
Gastric Cancer. 12:206–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Hironaka S, Zenda S, Boku N, Fukutomi A,
Yoshino T and Onozawa Y: Weekly paclitaxel as second-line
chemotherapy for advanced or recurrent gastric cancer. Gastric
Cancer. 9:14–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Egawa T, Kubota T, Nagashima A, Doi M,
Kitano M, Hayashi S, Yoshii H, Saikawa Y and Kitajima M: Usefulness
of weekly administration of paclitaxel for advanced or recurrent
gastric cancer. Jpn J Canc Chemother. 31:877–881. 2004.(In
Japanese).
|
|
7.
|
Koizumi W, Akiya T, Sato A, Yamaguchi K,
Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T and Sekikawa
T; Tokyo Cooperative Oncology Group (TCOG GI Group): Second-line
chemotherapy with biweekly paclitaxel after failure of
fluoropyrimidine-based treatment in patients with advanced or
recurrent gastric cancer: a report from the gastrointestinal
oncology group of the Tokyo Cooperative Oncology Group, TCOG
GC-0501 trial. Jpn J Clin Oncol. 39:713–719. 2009.
|
|
8.
|
Matsuda G, Kunisaki C, Makino H, et al:
Phase II study of weekly paclitaxel as a second-line treatment for
S-1-refractory advanced gastric cancer. Anticancer Res.
29:2863–2867. 2009.PubMed/NCBI
|
|
9.
|
Kodera Y, Ito S, Mchizuki Y, et al Chubu
Clinical Cancer Group: A phase II study of weekly paclitaxel as
second-line chemotherapy for advanced gastric cancer (CCOG0302
study). Anticancer Res. 27:2667–2671. 2007.PubMed/NCBI
|
|
10.
|
Chun JH, Kim HK, Lee JS, Choi JY, Lee HG,
Yoon SM, Choi IJ, Ryu KW, Kim YW and Bae JM: Weekly irinotecan in
patients with metastatic gastric cancer failing cisplatin-based
chemotherapy. Jpn J Clin Oncol. 34:8–13. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kawamura H, Yokota R, Watarai H, et al:
Third-line CPT-11 chemotheraphy for gastric cancer cases of
non-curative gastrectomy or recurrence. Jpn J Canc Chemother.
37:1051–1054. 2010.(In Japanese).
|
|
12.
|
Kuculzeybek Y, Dirican A, Erten C, Somali
I, Can A, Demir L, Bayoglu IV, Akyol M, Medeni M and Tarhan MO:
Second-line irinotecan after cisplatin, fluoropyrimidin and
docetaxel for chemotherapy of metastatic gastric cancer. Asian Pac
J Cancer Prev. 13:2771–2774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Oda H, Mizuno T, Yamashita Y, Nomura H,
Saito K, Tamaru S, Kageyama S and Katayama N: Irinotecan as
second-line chemotherapy for 5-FU-resistant gastric cancer with
disseminated intravascular coagulation: a case report. Jpn J Canc
Chemother. 38:1517–1520. 2011.(In Japanese).
|
|
14.
|
Goto A, Sukawa Y, Igarashi H, et al:
Irinotecan as the key chemotherapeutic agent in second-line
treatment of metastatic gastric cancer after failure of first-line
S-1 or S-1/CDDP therapy. Jpn J Canc Chemother. 38:1461–1466.
2011.(In Japanese).
|
|
15.
|
Farhat FS: A general review of the role of
irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol.
24:137–146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Fujitani K, Narahara H, Takiuchi H,
Tsujinaka T, Satomi E, Gotoh M, Hirao M, Furukawa H and Taguchi T:
Phase I and pharmacokinetic study of S-1 combined with weekly
paclitaxel in patients with advanced gastric cancer. Oncology.
69:414–420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kumagai K, Saikawa Y, Nakamura R,
Takahashi T, Kubota T, Kumai K, Kitagawa Y and Kitajima M: Clinical
experience of second-line chemotherapy with S-1/CPT-11 for highly
advanced gastric cancer. Jpn J Canc Chemother. 35:245–250. 2008.(In
Japanese).
|
|
18.
|
Komatsu Y, Yuki S, Fuse N, et al: Phase
1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients
with advanced gastric cancer. Adv Ther. 27:483–492. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Shitara K, Matsuo K, Mizota A, et al:
Association of fluoropyrimidines, platinum agents, taxanes, and
irinotecan in any line of chemotherapy with survival in patients
with advanced gastric cancer. Gastric Cancer. 14:155–160. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Thuss-Patience PC, Kretzschmar A, Bichev
D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G
and Reichardt P: Survival advantage for irinotecan versus best
supportive care as second-line chemotherapy in gastric cancer - a
randomized phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011.
View Article : Google Scholar
|
|
21.
|
Kang JH, Lee SI, Lim do H, et al: Salvage
chemotherapy for pretreated gastric cancer: a randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Akasaka O, Iwase S, Miwa H, Ando T, Morita
S, Koh R, Kasama M, Matsueda R and Anan H: Combination chemotherapy
of S-1 and CPT-11 for advanced recurrent gastric cancer. Jpn J Canc
Chemother. 36:1833–1837. 2009.(In Japanese).
|
|
23.
|
Kimura M, Usami E, Okada K, Nakao T,
Yoshimura T and Yasuda T: Safety evaluation for chemotherapy with
S-1 and cisplatin based on nutrition factors using body mass index
and serum albumin levels in patients with advanced and recurrent
gastric cancer. J Jpn Soc Hosp Pharm. 45:785–788. 2009.(In
Japanese).
|
|
24.
|
Kimura M, Morihata K, Ito D, Iwai M, Okada
K, Usami E, Nakao T, Yoshimura T and Yasuda T: Continuous
administration and safety of S-1 in adjuvant chemotherapy for
gastric cancer. Jpn J Canc Chemother. 37:829–834. 2010.(In
Japanese).
|
|
25.
|
Ueda S, Hironaka S, Yasui H, et al:
Randomized phase III study of irinotecan (CPT-11) versus weekly
paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to
combination chemotherapy (CT) of fluoropyrimidine plus platinum
(FP): WJOG4007 trial. J Clin Oncol. 30:(American Society of
Clinical Oncology, 48th Annual Meeting): abs. 4002. 2012.
|
|
26.
|
Shitara K, Matsuo K, Takahari D, et al:
Neutropenia as a prognostic factor in advanced gastric cancer
patients undergoing second-line chemotherapy with weekly
paclitaxel. Ann Oncol. 21:2403–2409. 2010. View Article : Google Scholar : PubMed/NCBI
|
